CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.